SRR10900021
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.600
- MYC_TARGETS_V1+0.500
- MYC_TARGETS_V2+0.500
- DNA_REPAIR+0.400
- E2F_TARGETS+0.400
- MTORC1_SIGNALING+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- CHOLESTEROL_HOMEOSTASIS+0.300
- FATTY_ACID_METABOLISM+0.300
- G2M_CHECKPOINT+0.300
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- ANGIOGENESIS-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- KRAS_SIGNALING_UP-0.400
- COAGULATION-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-46-3768-01A-01R-0980-07 | — | cohortSQ2 | 0.939 |
| 2 | TCGA-AN-A0AK-01A-21R-A00Z-07 | — | C | 0.916 |
| 3 | ULC0410T_S45 | — | cohortA4 | 0.911 |
| 4 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.910 |
| 5 | TCGA-21-1075-01A-01R-0692-07 | — | cohortSQ2 | 0.910 |
| 6 | MNG1063 | — | — | 0.910 |
| 7 | 9f6a2480-748d-414b-be0b-36be34c24037 | — | — | 0.903 |
| 8 | c6e243ee-b2d9-408e-ac05-ccbcffa805ab | — | — | 0.901 |
| 9 | SRR5088859 | — | — | 0.895 |
| 10 | s0094236 | — | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.600 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |